Mounjaro®
Starting from £179.99/mo
Start journey Learn moreEach Mounjaro KwikPen delivers a fixed volume of 0.5 ml per injection, regardless of which strength you are using. The concentration of tirzepatide varies by dose, but the liquid volume you inject stays the same across all six UK strengths. That means the 2.5 mg pen and the 15 mg pen feel identical in the hand and deliver the same amount of fluid — only the amount of active medicine dissolved in that fluid differs. These are prescription-only medicines; a GPhC-registered prescriber decides which strength is clinically right for you, and the volume question is one a prescriber at our clinical team can walk you through properly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people arrive at this question because they want to know whether switching to a higher strength means injecting more liquid. It doesn't. A question our prescribers hear most weeks is some version of: "the pen looks exactly the same, has anything actually changed?" The honest answer is that the pen body, the needle, and the 0.5 ml volume per dose are all identical. What changes is the concentration of tirzepatide dissolved inside it.
Think of it like squash: the same glass of water, progressively stronger. The 5 mg strength contains 5 mg of tirzepatide in that 0.5 ml; the 10 mg strength contains 10 mg in the same 0.5 ml. Eli Lilly has engineered the formulation this way so that the injection experience stays consistent as the dose escalates, which matters for comfort and for accurate dosing. If you want a precise breakdown of how each Mounjaro dose translates in ml, that page covers the concentration figures across all UK strengths in detail. The full breakdown of how each UK strength is structured can be found on the Mounjaro dose guide, which covers all six strengths in detail.
The NHS medicines page for tirzepatide is a reliable starting point if you want the patient-level summary of how the pen works, including the injection process itself.
Each KwikPen is pre-filled with 2 ml of solution. That's four individual 0.5 ml doses, released one at a time, one per week. The pen has an internal counter that tracks how many doses remain, so you don't have to measure anything yourself. There's no plunger to depress a set distance and no marking you need to read; the pen manages it mechanically.
This is different from some insulin pens and older injectable medicines where patients do draw up doses in a syringe and need to read a marking in ml. With Mounjaro, that step doesn't exist. The pen clicks, delivers 0.5 ml, and stops. What you're paying attention to is the dose counter, not the barrel.
If you're comparing how the standard KwikPen format differs from the single-dose presentation that some patients use, the Mounjaro single-dose pen page covers that distinction clearly. The ml volume per injection remains 0.5 ml in both formats; the difference is in how the pen is supplied and used.
For anyone looking at the 5 mg strength specifically, our page explaining how the Mounjaro 5 mg pen is supplied across its five doses goes into the concentration figures for that strength in more detail, and if you're also wondering how 5 doses fit inside a single Mounjaro pen, that page walks through exactly how the pen is structured to deliver them.
The clinical decision your prescriber makes is based on milligrams, not millilitres. Titration follows the licensed schedule: treatment in the UK starts at 2.5 mg for the first four weeks, primarily to let your system adjust, and the prescriber increases from there in steps (typically 2.5 mg at a time) based on how you're tolerating the current strength and whether your weight response warrants moving up.
Knowing that you're injecting 0.5 ml tells you nothing about where you are therapeutically. A patient on 2.5 mg and a patient on 15 mg are both injecting the same volume; one is at the very beginning of treatment and the other is at the highest licensed UK strength, which in the SURMOUNT-1 trial was associated with around 20–21% average body-weight reduction over 72 weeks, cited in the SURMOUNT-1 paper in the New England Journal of Medicine. Those are very different clinical situations arriving in the same-sized injection.
This is part of why self-adjusting doses based on the liquid volume you see is not something the pen supports, and not something a prescriber would advise. Titration timing and decisions belong in the consultation. You can read more about what treatment involves on the Mounjaro overview page, or explore weight-loss treatment options if you're still working out which path makes sense for you.
The three licensed injection sites are the abdomen, the front of the thigh, and the upper arm. Rotating between them reduces localised tissue reactions. A 0.5 ml subcutaneous injection is a modest volume (smaller than many standard injections) which is part of why most people find the process far less daunting than they expected. Mild redness or transience at the site is normal and usually settles within a day or two.
Common side effects across all strengths are gastrointestinal, nausea, loose stools, reduced appetite, indigestion. These tend to be most noticeable in the early weeks or after a dose increase, and generally settle as the body adjusts. Storage is refrigerated at 2–8°C; for the precise room-temperature window the pen can tolerate outside the fridge, the Patient Information Leaflet is the authoritative source. The nume FAQs also cover storage and administration questions that come up regularly.
If you have questions about your current treatment or want a clinical view on your dose, our prescribers review consultations the same working day. Speak to our prescribers through the free consultation, there's no obligation, and the whole process takes a few minutes to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.